Status:

RECRUITING

The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT

Lead Sponsor:

Anhui Provincial Hospital

Conditions:

Hematopoietic Recovery

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

Brief Summary

To assess the safety and efficacy of coenzyme I for injection in promoting hematopoietic recovery after single-unit unrelated cord blood transplantation in hematological malignancies.

Detailed Description

A single-center, open-label, dose-escalation study to assess the safety and efficacy of coenzyme I for injection in promoting hematopoietic recovery after single-unit unrelated cord blood transplantat...

Eligibility Criteria

Inclusion

  • Age between 18 and 60 years (inclusive) at screening; gender is not restricted;
  • Diagnosed with hematological malignancies to receive sUCBT for the first time;
  • No severe organ failure and no active infections
  • ECOG performance status of 0-2;
  • Voluntarily participating in the clinical trial, with full understanding of the trial details and having signed the informed consent form.

Exclusion

  • Those with severe organ dysfunction or disease, such as severe disease and dysfunction of the heart, liver, kidneys and pancreas;
  • Pregnant patients;
  • Patients and/or authorised family members who refuse to receive Coenzyme I for Injection;
  • Any life-threatening disease, physical condition, or organ system dysfunction that, in the opinion of the investigator, may compromise patient safety and put the results of the study at undue risk; drug-dependent individuals; patients with uncontrolled psychiatric disorders; and individuals with cognitive impairment;
  • Participants in other clinical studies affecting hematopoietic recovery within 3 months;
  • Those who are considered by the investigator to be unsuitable for enrolment (e.g., those who anticipate that the patient will not be able to adhere to the examination and treatment due to financial or other issues).

Key Trial Info

Start Date :

November 29 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2026

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT06558253

Start Date

November 29 2024

End Date

September 30 2026

Last Update

December 18 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

Hefei, Anhui, China, 230036